Bionano Genomics, Inc.

code applications, they'll be familiar with not only the methodology, which is what the focus of the CPT code process is on, but of the value and utilization. And that's driving coverage. And so I think CPT codes will be important. They're going to get out there eventually down the road. They're certainly going to be important when FDA cleared, mapping systems are available and labs that are adopting them are using FDA-cleared versions of the system. Our focus is on unlocking coverage right now because we see plenty of coding happening.

That's helpful. And in terms of the publications regarding the hematological malignancy publication that came out, the three of them, what are the next steps? Do you need additional studies in terms of you know, starting conversations with guideline bodies to make OGM first here. I'm wondering what the next steps are.

No, it's a great question. I think that the strategy to evolve optical genome mapping from a basic research tool into something that's used routinely and regularly in translational research, I think that that's what we're seeing now, into something that eventually gets recommended and becomes part of the standard of care, involves getting a lot of data out, what I call critical mass of data, and a key component of that strategy is to work with folks in the field who are associated with the teams that make recommendations to these medical societies. So if you look at some of these publications that are coming out, the three that we talked about earlier this quarter are from European sites, but we have others. There was a really amazing publication last summer that came out of MD Anderson Cancer Center. All of these authors have an affiliation, or several of these authors have affiliations with guideline-setting agencies, such as the World Health Organization, NCCN here, National Comprehensive Cancer Network in the United States. And those those agencies set those guidelines. And so by working with key opinion leaders who are already affiliated there, it's a way of accelerating the process.